Wonder Drake
Last active: 7/20/2016


I am interested in exploring the etiology as well as pathogenesis of chronic inflammatory states, particularly sarcoidosis. I am currently using polymerase chain reactions to investigate possible infectious etiologies of sarcoidosis. We are also using techniques such as in situ hybridization to directly localize microbial nucleic acid in the tissue specimens and molecular microarrays in collaboration with our colleagues at Cleveland Clinic, and Medical University of South Carolina.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP (2016) Am J Respir Cell Mol Biol 55(1): 128-34
    › Primary publication · 26807608 (PubMed) · PMC4942207 (PubMed Central)
  2. The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis. Celada LJ, Hawkins C, Drake WP (2015) Clin Chest Med 36(4): 561-8
    › Primary publication · 26593133 (PubMed) · PMC4660257 (PubMed Central)
  3. Solving the Conundrum: Immunogenetics of Sarcoidosis. Kaminski N, Drake WP (2015) Am J Respir Crit Care Med 192(6): 652-4
    › Primary publication · 26371809 (PubMed) · PMC4595685 (PubMed Central)
  4. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) Study. Sarcoidosis Protocol. Moller DR, Koth LL, Maier LA, Morris A, Drake W, Rossman M, Leader JK, Collman RG, Hamzeh N, Sweiss NJ, Zhang Y, O'Neal S, Senior RM, Becich M, Hochheiser HS, Kaminski N, Wisniewski SR, Gibson KF, GRADS Sarcoidosis Study Group (2015) Ann Am Thorac Soc 12(10): 1561-71
    › Primary publication · 26193069 (PubMed) · PMC4627423 (PubMed Central)
  5. Resolution of chronic ocular sarcoidosis with antimycobacterial therapy. Richmond BW, Richter K, King LE, Drake WP (2014) Case Rep Intern Med 1(2)
    › Primary publication · 25580448 (PubMed) · PMC4286311 (PubMed Central)
  6. Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy? Celada LJ, Drake WP (2015) Immunotherapy 7(1): 57-66
    › Primary publication · 25572480 (PubMed) · PMC5737958 (PubMed Central)
  7. Association of HLA-DRB1 with Sarcoidosis Susceptibility and Progression in African Americans. Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, Drake WP, Montgomery CG, Rybicki BA (2015) Am J Respir Cell Mol Biol 53(2): 206-16
    › Primary publication · 25506722 (PubMed) · PMC4566045 (PubMed Central)
  8. A pilot study of the noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia. May AK, Brady JS, Romano-Keeler J, Drake WP, Norris PR, Jenkins JM, Isaacs RJ, Boczko EM (2015) Chest 147(6): 1494-1502
    › Primary publication · 25474571 (PubMed) · PMC4451706 (PubMed Central)
  9. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity. Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, Grutters J, Culver DA, Dworski R, Sheller J, Massion PP, Polosukhin VV, Johnson JE, Kaminski N, Wilkes DS, Oswald-Richter KA, Drake WP (2014) Am J Respir Crit Care Med 190(5): 560-71
    › Primary publication · 25073001 (PubMed) · PMC4214083 (PubMed Central)
  10. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, Shipley GR (2013) Sarcoidosis Vasc Diffuse Lung Dis 30(3): 201-11
    › Primary publication · 24284293 (PubMed) · PMC3929334 (PubMed Central)
  11. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, Braun N, Taylor T, Pandit KV, Aboud C, Yu C, Kaminski N, Boyd AS, King LE (2013) JAMA Dermatol 149(9): 1040-9
    › Primary publication · 23863960 (PubMed) · PMC3927541 (PubMed Central)
  12. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. Oswald-Richter KA, Richmond BW, Braun NA, Isom J, Abraham S, Taylor TR, Drake JM, Culver DA, Wilkes DS, Drake WP (2013) J Immunol 190(11): 5446-53
    › Primary publication · 23630356 (PubMed) · PMC3660530 (PubMed Central)
  13. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, Abraham S, Mageto Y, Culver DA, Oswald-Richter KA, Drake WP (2013) J Clin Immunol 33(2): 446-55
    › Primary publication · 23073617 (PubMed) · PMC3850764 (PubMed Central)
  14. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, Culver DA, Caprioli RM, Drake WP (2012) J Clin Immunol 32(5): 1129-40
    › Primary publication · 22552860 (PubMed) · PMC3526106 (PubMed Central)
  15. Where next for gene expression profiling? So much promise. Noth I, Gibson KF, Drake WP (2011) Am J Respir Crit Care Med 184(10): 1102-3
    › Primary publication · 22086986 (PubMed)
  16. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Oswald-Richter KA, Beachboard DC, Zhan X, Gaskill CF, Abraham S, Jenkins C, Culver DA, Drake W (2010) Respir Res : 161
    › Primary publication · 21092305 (PubMed) · PMC2999599 (PubMed Central)
  17. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Oswald-Richter KA, Drake WP (2010) Semin Respir Crit Care Med 31(4): 375-9
    › Primary publication · 20665387 (PubMed)
  18. Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Richmond BW, Drake WP (2010) Curr Opin Pulm Med 16(5): 461-4
    › Primary publication · 20473167 (PubMed)
  19. Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, Drake JM, Culver DA, Drake WP (2011) Am J Respir Cell Mol Biol 44(2): 166-74
    › Primary publication · 20348207 (PubMed) · PMC3049230 (PubMed Central)
  20. Single-chain urokinase in empyema induced by Pasturella multocida. Idell S, Jun Na M, Liao H, Gazar AE, Drake W, Lane KB, Koenig K, Komissarov A, Tucker T, Light RW (2009) Exp Lung Res 35(8): 665-81
    › Primary publication · 19895321 (PubMed)
  21. Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Oswald-Richter KA, Culver DA, Hawkins C, Hajizadeh R, Abraham S, Shepherd BE, Jenkins CA, Judson MA, Drake WP (2009) Infect Immun 77(9): 3740-8
    › Primary publication · 19596780 (PubMed) · PMC2738026 (PubMed Central)
  22. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. Oswald-Richter K, Sato H, Hajizadeh R, Shepherd BE, Sidney J, Sette A, Newman LS, Drake WP (2010) J Clin Immunol 30(1): 157-66
    › Primary publication · 19536643 (PubMed) · PMC2821522 (PubMed Central)
  23. Infectious antigens may play a role in the pathogenesis of sarcoidosis. Drake W (2008) Medscape J Med 10(12): 288
    › Primary publication · 19242594 (PubMed) · PMC2644019 (PubMed Central)
  24. When a commensal becomes a pathogen. Drake WP (2008) Sarcoidosis Vasc Diffuse Lung Dis 25(1): 10-1
    › Primary publication · 19070255 (PubMed)
  25. Mycobacterial infection masquerading as cutaneous sarcoidosis. Moss J, Zic J, Drake W (2009) Clin Exp Dermatol 34(5): e199-201
    › Primary publication · 19040506 (PubMed)
  26. Superoxide dismutase A antigens derived from molecular analysis of sarcoidosis granulomas elicit systemic Th-1 immune responses. Allen SS, Evans W, Carlisle J, Hajizadeh R, Nadaf M, Shepherd BE, Pride DT, Johnson JE, Drake WP (2008) Respir Res : 36
    › Primary publication · 18439270 (PubMed) · PMC2383887 (PubMed Central)
  27. Multiple Mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells. Carlisle J, Evans W, Hajizadeh R, Nadaf M, Shepherd B, Ott RD, Richter K, Drake W (2007) Clin Exp Immunol 150(3): 460-8
    › Primary publication · 17924974 (PubMed) · PMC2219367 (PubMed Central)
  28. Mycobacterium tuberculosis Antigen 85A induces Th-1 immune responses in systemic sarcoidosis. Hajizadeh R, Sato H, Carlisle J, Nadaf MT, Evans W, Shepherd BE, Miller RF, Kalams SA, Drake WP (2007) J Clin Immunol 27(4): 445-54
    › Primary publication · 17357846 (PubMed) · PMC3962023 (PubMed Central)
  29. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Drake WP, Dhason MS, Nadaf M, Shepherd BE, Vadivelu S, Hajizadeh R, Newman LS, Kalams SA (2007) Infect Immun 75(1): 527-30
    › Primary publication · 17088357 (PubMed) · PMC1828402 (PubMed Central)
  30. Reactivation of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for acquired immunodeficiency syndrome. Drake WP, Byrd VM, Olsen NJ (2003) J Clin Rheumatol 9(3): 176-80
    › Primary publication · 17041454 (PubMed)
  31. Mycobacterial antigens may be important in sarcoidosis pathogenesis. Drake WP, Newman LS (2006) Curr Opin Pulm Med 12(5): 359-63
    › Primary publication · 16926652 (PubMed)
  32. Molecular analysis of sarcoidosis tissues for mycobacterium species DNA. Drake WP, Pei Z, Pride DT, Collins RD, Cover TL, Blaser MJ (2002) Emerg Infect Dis 8(11): 1334-41
    › Primary publication · 12453366 (PubMed) · PMC2738555 (PubMed Central)